Patents by Inventor Maria T. Arevalo

Maria T. Arevalo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA interference-based therapeutic against anthrax
    Patent number: 10479998
    Abstract: The present invention includes siRNAs and antibodies that block the interaction between TEM8 and/or CMG2 cell surface proteins and anthrax toxin and methods of treating anthrax exposure with the same.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: November 19, 2019
    Assignee: Texas Tech University System
    Inventors: Mingtao Zeng, Maria T. Arevalo
  • Dual purpose universal influenza vaccine confers protective immunity against anthrax
    Patent number: 10370416
    Abstract: The present invention includes antigenic fusion proteins, nucleic acids encoding the fusion proteins and methods of making and using the same, wherein the fusion protein comprises three or more different influenza A ectodomains of Matrix Protein 2 (M2e); one or more stem regions of an influenza A hemagglutinin 2 (HA2) protein; and optionally an anthrax antigen, wherein the fusion protein is immunogenic across strains.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: August 6, 2019
    Assignee: Texas Tech University System
    Inventors: Mingtao Zeng, Maria T. Arevalo, Junwei Li
  • RNA Interference-Based Therapeutic Against Anthrax
    Publication number: 20180112223
    Abstract: The present invention includes siRNAs and antibodies that block the interaction between TEM8 and/or CMG2 cell surface proteins and anthrax toxin and methods of treating anthrax exposure with the same.
    Type: Application
    Filed: December 12, 2017
    Publication date: April 26, 2018
    Inventors: Mingtao Zeng, Maria T. Arevalo
  • RNA interference-based therapeutic against anthrax
    Patent number: 9862951
    Abstract: The present invention includes siRNAs and antibodies that block the interaction between TEM8 and/or CMG2 cell surface proteins and anthrax toxin and methods of treating anthrax exposure with the same.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: January 9, 2018
    Assignee: Texas Tech University System
    Inventors: Mingtao Zeng, Maria T. Arevalo
  • Dual Purpose Universal Influenza Vaccine Confers Protective Immunity Against Anthrax
    Publication number: 20170253636
    Abstract: The present invention includes antigenic fusion proteins, nucleic acids encoding the fusion proteins and methods of making and using the same, wherein the fusion protein comprises three or more different influenza A ectodomains of Matrix Protein 2 (M2e); one or more stem regions of an influenza A hemagglutinin 2 (HA2) protein; and optionally an anthrax antigen, wherein the fusion protein is immunogenic across strains.
    Type: Application
    Filed: March 1, 2017
    Publication date: September 7, 2017
    Inventors: Mingtao Zeng, Maria T. Arevalo, Junwei Li
  • RNA Interference-Based Therapeutic Against Anthrax
    Publication number: 20160145627
    Abstract: The present invention includes siRNAs and antibodies that block the interaction between TEM8 and/or CMG2 cell surface proteins and anthrax toxin and methods of treating anthrax exposure with the same.
    Type: Application
    Filed: June 12, 2014
    Publication date: May 26, 2016
    Inventors: Mingtao Zeng, Maria T. Arevalo
  • COMPOSITIONS AND METHODS FOR INHIBITION OF OR TREATMENT OF DENGUE VIRUS INFECTION
    Publication number: 20130189275
    Abstract: The present invention relates to a method of interfering with dengue infection comprising interfering with dengue virus binding to a syndecan present on a cell targeted by dengue virus. The present invention further relates to treating a patient for dengue virus infection comprising administering to a patient, either having a dengue infection or a patient exposed to dengue infection, an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus. The present invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier, and an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus.
    Type: Application
    Filed: June 3, 2011
    Publication date: July 25, 2013
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Maria T. Arevalo, Patricia J. Simpson-Haidaris, Xia Jin, Huiyan Chen, Matthew H. Quinn